TAG:
laboratory industry
LabCorp’s MacMahon Provides Insights About Lab Marketplace
By Robert Michel | From the Volume X No. 5 – April 14, 2003 Issue
CEO SUMMARY: Pathologists will be particularly interested in what Thomas MacMahon has to say about the evolution of laboratory medicine. As Chairman, President, and CEO of Laboratory Corporation of America Holdings, he has continuous access to some of the best strategic analysis about the…
Why Patient Safety Is Change Agent for Labs
By Robert Michel | From the Volume X No. 4 – March 24, 2003 Issue
CEO SUMMARY: In the 1990s, managed care was the dominant change agent to the nation’s healthcare system. During the 2000s, it will be patient safety. However, unlike the unpleasant consequences of HMOs, capitation, and utilization risk, patient safety will prove to be a benevolent trend…
Needless Mastectomy Draws National Attention
By Robert Michel | From the Volume X No. 2 – February 10, 2003 Issue
CEO SUMMARY: This widely-reported case of misdiagnosis at an Allina hospital in St. Paul, Minnesota is a powerful reminder to pathology practices and clinical laboratories that breakdowns in medical quality will draw increasing attention and scrutiny. Both the patient and the community ar…
New Trends in 2003 Affect Clinical Lab Services
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: Here’s our current list of macro trends that affect clinical laboratories, updated from the last list in January 2000. One bold prediction is that Medicare, as we know it, is on the verge of a major meltdown. Employers and consumers are also new forces to be reckoned with b…
New Market Channel For Esoteric Testing
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
Laboratories Sit Squarely Between New Genetics and Today’s Medicine
By Robert Michel | From the Volume IX No. 18 – December 30, 2002 Issue
“Clinical laboratories and pathology groups are at the leading edge of the genetic revolution.” —Rick J. Carlson. CEO SUMMARY: Healthcare futurist Rick J. Carlson believes that knowledge of the human genome will trigger revolutionary…
Patient Safety is Related to “Quality Management”
By R. Lewis Dark | From the Volume IX No. 17 – December 9, 2002 Issue
REMEMBER BACK IN 1997 WHEN LABORATORY COMPLIANCE PROGRAMS were mandated by Medicare officials? That was a big thing in the laboratory industry. Every laboratory organization in the United States scrambled to assess their laboratory’s operating practices, develop policies, and create a compliance ma…
Several Major Surprises Mark Events of 2002
By Robert Michel | From the Volume IX No. 17 – December 9, 2002 Issue
CEO SUMMARY: It was a year when the two blood brothers got much bigger and expanded market share by buying their largest competitors. With patient safety as the goal, employers began active steps to force hospitals, physicians, and other healthcare providers to use quality management syst…
It’s a Feud in North Carolina! LabCorp Versus Spectrum
By Robert Michel | From the Volume IX No. 17 – December 9, 2002 Issue
OVER IN NORTH CAROLINA, one of those good, old-fashioned southern feuds is under way. Like the fabled feud between the Hatfields and the McCoys of years past, Spectrum Laboratory Network and Laboratory Corporation are in a full-fledged shoot-out over market share of…
More Consolidation: Where Will It Lead?
By R. Lewis Dark | From the Volume IX No. 16 – November 18, 2002 Issue
I CERTAINLY DID NOT FORESEE ALL THE LAB ACQUISITION ACTIVITY that occurred during 2002. Compared to recent years, both Quest Diagnostics Incorporated and Laboratory Corporation of America have been on a buying spree this year. Quest Diagnostics acquired Amer…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized